AlloMap Molecular Expression Testing
AlloMap molecular expression testing, developed and commercialized by XDx, is a gene expression profiling test to identify heart transplant recipients with a low probability of one type of transplant rejection. The test is performed on a blood sample, providing a non-invasive test to help manage the care of patients post transplant. Prior to the availability of this test, the primary method for managing heart transplant rejection was the invasive technique of endomyocardial biopsy.
Test results are reported as a single score indicating the probability of moderate/severe acute cellular rejection (ACR). The performance characteristics of the test make it best suited to help indicate that acute cellar rejection is not present. The score is based on the amount of RNA from each gene in a 20-gene panel comprising 11 rejection-related genes and 9 genes used for normalization and quality control. Many of the rejection-related genes are associated with biological pathways involved in the immune response and rejection processes.
The test score is used, along with other standard clinical assessments, to evaluate the patient’s probability of acute cellular rejection and the need for additional evaluations. This test is not designed to be informative about other forms of heart rejections such as antibody-mediated rejection (AMR) or cardiac allograft vasculopathy (CAV).
AlloMap has been commercially available since 2005 as a CLIA approved Laboratory Developed Test (LDT) and was cleared by the U.S. Food and Drug Administration (FDA) in 2008 as a Class II Medical Device. It is available only from the XDx Reference Laboratory in Brisbane, CA.
The use of the test is described in the recommendations for the non-invasive monitoring of acute heart transplant rejection in the first evidence-based clinical practice guidelines for the care of heart transplant recipients issued by the International Society of Heart and Lung Transplantation.

This is an excerpt from the article AlloMap Molecular Expression Testing from the Wikipedia free encyclopedia. A list of authors is available at Wikipedia.
The article AlloMap Molecular Expression Testing at en.wikipedia.org was accessed 344 times in the last 30 days. (as of: 04/21/2014)
Images on AlloMap Molecular Expression Testing
Preview image:
Original:
Search results from Google and Bing
1
1
1
AlloMap Molecular Expression Testing
AlloMap® molecular expression testing is a noninvasive, multi-gene, multi- pathway gene expression test that enables physicians to distinguish rejection from ...
www.allomap.com/
2
>30
2
Helpful Terms and FAQs - AlloMap Molecular Expression Testing
Gene: Basic unit of heredity found in your cells. DNA: A chemical inside the nucleus of a cell that carries the genetic instructions. The DNA structure is a double ...
allomap.com/patients-faq.html
3
>30
3
Patients & Caregivers - AlloMap Molecular Expression Testing
Testing. The AlloMap® Testing Process. AlloMap is an innovative test that uses a blood sample to help doctors manage the care of stable heart transplant ...
www.allomap.com/patients.html
4
>30
4
AlloMap molecular expression testing - Wikipedia, the free ...
AlloMap Molecular Expression Testing, developed and commercialized by XDx, is a gene expression profiling test to identify heart transplant recipients with a low ...
en.wikipedia.org/wiki/AlloMap_molecular_expression_testing
5
>30
5
Clinical Review Criteria: AlloMap (Molecular Expression Testing ...
Group Health Cooperative. All Rights Reserved. Clinical Review Criteria. Laboratory Tests for Detection of Heart Transplantation Rejection. AlloMap (Molecular ...
provider.ghc.org/all-sites/clinical/criteria/pdf/allomap.pdf;jsessionid=03LBRVXVUVDNRJCISQ3SGWQ
6
>30
6
IMAGE: A Comparison of AlloMap Molecular Testing and Traditional ...
Jul 11, 2006 ... Graft Rejection Heart Diseases, Device: AlloMap Molecular Expression Testing. Procedure: Right ventricular endomyocardial biopsy ...
clinicaltrials.gov/show/NCT00351559
7
>30
7
The AlloMap Testing Service - XDx
AlloMap® Molecular Expression Testing is an innovative test that uses genomic technologies to help physicians care for heart transplant patients. When used in ...
www.xdx.com/documents/Product%20Literature/LQ10007_AlloMap_HTx_Monograph_ecopy.pdf
8
>30
8
XDx - Expression Diagnostics
The company's first commercial service, AlloMap Molecular Expression Testing is a noninvasive, multi-gene, multi-pathway gene expression test that enables ...
www.xdx.com/
9
>30
9
XDx Launches AlloMap® Molecular Expression Testing in Germany ...
Apr 4, 2012 ... XDx, Inc., a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value ...
www.businesswire.com/news/home/20120404005446/en/XDx-Launches-AlloMap%C2%AE-Molecular-Expression-Testing-Germany
>30
2
10
AlloMap | Facebook
AlloMap. 207 likes · 3 talking about this. XDx XDx, a life sciences company based in Brisbane, California, is dedicated to improving the standard of care given to ...
www.facebook.com/AlloMap
Search results for "AlloMap Molecular Expression Testing"
Google: approx. 5.830
bing: approx. 17
AlloMap Molecular Expression Testing in science
IMAGE: A Comparison of AlloMap Molecular Testing and Traditional ...
Jul 11, 2006 ... Device: AlloMap Molecular Expression Testing. Procedure: .... Columbia University Medical Center - New York Presbyterian Hospital. New York ...
Getting Tested - AlloMap Molecular Expression Testing
The company's first commercial service, AlloMap Molecular Expression Testing is a noninvasive, multi-gene, multi-pathway gene expression test that enables ...
Allomap ® Videos - AlloMap Molecular Expression Testing
... first commercial service, AlloMap Molecular Expression Testing is a noninvasive , ... Failure/Transplant faculty in the Cardiovascular Institute at the University of ...
Gene Expression Test Reduces Need for Invasive Heart Muscle ...
Apr 23, 2010 ... AlloMap Molecular Expression Testing is a service provided by XDx ... Dr. Michael Pham and Dr. Hannah Valantine of Stanford University ...
[PDF]XDx Announces Presentations at Upcoming 2013 International ...
Apr 27, 2013 ... Johan Vanhaecke, MD, from Leuven University Medical Center, will be ... AlloMap Molecular Expression Testing is a non-invasive gene ...
Drexel University College of Medicine Offers Advanced Test to Heart ...
Nov 14, 2008 ... The latest news from Drexel University College of Medicine as well as ... AlloMap ™ molecular expression testing, developed by XDx, uses a ...
Gene Test Detects Heart Transplant Rejection - Morgan Stanley ...
Columbia University Medical Center .... AlloMap Molecular Expression Testing is a service provided by XDx through its clinical laboratory, which is CLIA- (Clinical ...
Gene expression test reduces need for invasive heart muscle biopsy
Apr 27, 2010 ... AlloMap Molecular Expression Testing is a service provided by XDx ... Dr. Michael Pham and Dr. Hannah Valantine of Stanford University ...
Accuracy Of Gene Expression Test For Heart Transplant Patients ...
Dec 21, 2006 ... Columbia University Medical Center ... gene expression profiling (GEP) test, called AlloMap® molecular expression test, which led to the test's ...
Gene test for heart rejection update article - LISTSERV 15.5 ...
Jan 6, 2006 ... The gene-expression test, called AlloMap™ molecular expression ... research at Columbia University Medical Center, assistant professor of ...
Books on the term AlloMap Molecular Expression Testing
Essentials of Genomic and Personalized Medicine
Essentials of Genomic and Personalized Medicine
Geoffrey S. Ginsburg, Huntington F Willard, 2009
Candidate gene selection 285 CARGO samples tested with a leukocyte microarray Database and literature mining ... Development of a 20-gene algorithm to distinguish rejection from quiescence (AlloMap Molecular Expression Testing) ...
In Situ Molecular Pathology and Co-Expression Analyses
In Situ Molecular Pathology and Co-Expression Analyses
Gerard J. Nuovo, 2013
In Situ Molecular Pathology and Co-Expression Analyses explains, in easy-to-understand language, simplified ways of understanding and performing in situ hybridization and immunohistochemistry tests. The book also focuses on straightforward protocols used to simultaneously detect two or more proteins/nucleic acids within intact tissue by doing co-ex...
Genomic and Personalized Medicine
Genomic and Personalized Medicine
Geoffrey S. Ginsburg, Huntington F. Willard, 2012
Based on the CARGO study results, the GEP test was commercialized as AlloMap® Molecular Expression Testing by XDx, Inc. in Brisbane, CA. The test employs triplicate qRT-PCR assays for each of the 20 genes, and reports an AlloMap® ...
Transplantation Immunology: Methods and Protocols (Methods in Molecular Biology)
Transplantation Immunology: Methods and Protocols (Methods in Molecular Biology)
Andrea A. Zachary and Mary S. Leffell, 2013
After decades of research in clinical transplantation, new techniques have been developed that permit a further understanding of the immune mechanisms underlying immune recognition of allografts and a more accurate and thorough evaluation of compatibility between donors and recipients. The second edition of Transplantation Immunology: Methods and P...
Genomic and Personalized Medicine
Genomic and Personalized Medicine
2012
Based on the CARGO study results, the GEP test was commercialized as AlloMap® Molecular Expression Testing by XDx, Inc. in Brisbane, CA. The test employs triplicate qRT-PCR assays for each of the 20 genes, and reports an AlloMap® ...
Diffusion and Use of Genomic Innovations in Health and Medicine: ...
Diffusion and Use of Genomic Innovations in Health and Medicine: ...
Roundtable on Translating Genomic-Based Research for Health, 2008
Uncertainty about new test interpretations may affect the adoption decisions of health care providers. For example, the AlloMap molecular expression test was developed to detect acute cellular rejection in heart- transplant patients.
Blood Tests: Electrolyte, Glucose Tolerance Test, Hiv Test, ...
Blood Tests: Electrolyte, Glucose Tolerance Test, Hiv Test, ...
Source Wikipedia, Books Llc, 2010
Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online.
Development of Google searches


Blog posts on the term
AlloMap Molecular Expression Testing
A Second Heart: A is for Allomap Molecular Expression Testing
I have decided to participate in the Blogging from A to Z Challenge and since I have recently realized how much I DON'T know about heart function, heart diagnostics, etc. I have decided to use a theme of heart disease and make it to treatment.
asecondheart.blogspot.com/2012/04/is-for-allomap-molecular-expression.html
Merv Sheppard's Transplant Network: Now in Canada - Blood test identifies probability of rejection in heart recipients
MISSISSAUGA, ONTARIO and BRISBANE, CALIFORNIA -- (Marketwired) -- 06/20/13 -- CML HealthCare Inc. (TSX:CLC) (the "Company" or "CML HealthCare"), a leading provider of medical diagnostic services in Canada, and XDx, Inc.
mervsheppard.blogspot.com/2013/06/now-in-canada-blood-test-identifies.html
Diaxonhit and XDx Sign Exclusive European AlloMop Deal | Pharma » The Global Magazine for the Pharmaceutical Industry
The essential source of biopharmaceutical and pharmaceutical industry news
www.pharma-mag.com/diaxonhit-and-xdx-enter-into-a-memorandum-of-agreement-for-the-exclusive-license-to-market-and-perform-allomap-in-europe/
Diaxonhit Agrees to Commercialize in Europe the XDx AlloMap® Heart Transplant Test Following the Completion of Exclusive License Agreement | FDA News
fda.ulitzer.com/node/2718347
peHUB | Private equity and venture capital news, data and community
XDx Inc. , a Brisbane, Calif.
www.pehub.com/2009/08/05/xdx-raises-144-million-after-pulling-ipo/
theheart.org: trusted cardiology news and opinions
The latest developments in cardiology and cardiovascular research, including heartwire news and commentary by some of the world's top cardiologists. Sign up for free.
www.theheart.org/article/1389173.do
Gene Expression Test Reduces Need for Invasive Heart Muscle Biopsy
Monitoring rejection in heart transplantation patients with a simple blood test co-developed by NewYork-Presbyterian Hospital/Columbia University Medical Center physician-scientist Dr. Mario Deng in 2005 can safely reduce their need for invasive heart-muscle biopsies, a new study has found.
www.newswise.com/articles/gene-expression-test-reduces-need-for-invasive-heart-muscle-biopsy
In Brief This Week: Thermo Fisher; ISI Group, BD; Diagenode; Diaxonhit, XDx; Swift Biosciences; Rancho BioSciences | GenomeWeb Daily News | GenomeWeb
 
www.genomeweb.com/brief-week-thermo-fisher-isi-group-bd-diagenode-diaxonhit-xdx-swift-biosciences
Health Tech: Economics Can Play an Unusual Role in Entrance to Market « Popper and Co.
A case study showing how economics can sometimes interfere with mass market adoption, to the detriment of patients.
popperandco.com/2011/04/health-tech-economics-can-play-an-unusual-role-in-entrance-to-market/
Gene Test Detects Heart Transplant Rejection
A simple blood test may detect whether a chronic heart transplant patient is rejecting their heart, and may reduce the need for invasive heart-muscle biopsies, according to the results of a multi-center study called CARGO (Cardiac Allograft Rejection Gene Expression Observational Study), led by NewYork-Presbyterian Hospital and Columbia University Medical Center and published in the December 19 The American Journal of Transplantation. The findings describe a new methodology that may impact the way heart transplant patients are treated. The four-year, eight-site CARGO study included data from centers accounting for approximately 22 percent of the yearly U.S. heart transplant population.
weill.cornell.edu/news/releases/nyp/nyp_2005/12_15_05.shtml
123